As shown in Figure 5H,I, after discontinuing second-line therapy, treatment with anti-CTLA-4 antibody combined with regorafenib plus chidamide-k30 achieved an OS of 87.5%, while anti-CTLA-4 antibody combined with cabozantinib plus chidamide-k30 group achieved an OS of 71.4%, thus indicating possible immune system activation to inhibit tumor cell growth and avoid relapse, as shown in Table 4. This evidence concerns the gene CTLA4 and neoplasm.